Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.

Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ.

J Urol. 1999 Feb;161(2):529-33.

PMID:
9915441
2.

Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000.

Mullan RJ, Jacobsen SJ, Bergstralh EJ, Slezak JM, Tindall DJ, Lieber MM, Roberts RO.

BJU Int. 2005 May;95(7):951-5.

3.

Trends in prostate cancer mortality among black men and white men in the United States.

Chu KC, Tarone RE, Freeman HP.

Cancer. 2003 Mar 15;97(6):1507-16.

4.

Prostate cancer and prostate-specific antigen testing in New South Wales.

Smith DP, Supramaniam R, Marshall VR, Armstrong BK.

Med J Aust. 2008 Sep 15;189(6):315-8.

PMID:
18803534
6.

Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996.

Threlfall TJ, English DR, Rouse IL.

Med J Aust. 1998 Jul 6;169(1):21-4.

PMID:
9695697
7.

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS.

J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24.

8.
9.

Prostate cancer incidence and mortality rates and trends in the United States and Canada.

McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD.

Public Health Rep. 2004 Mar-Apr;119(2):174-86.

10.

Prostate cancer trends in Canada: rising incidence or increased detection?

Levy IG, Gibbons L, Collins JP, Perkins DG, Mao Y.

CMAJ. 1993 Sep 1;149(5):617-24.

11.

A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.

Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber MM, Jacobsen SJ.

J Urol. 2005 Jun;173(6):2048-53.

PMID:
15879823
13.

Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.

Roberts RO, Bergstralh EJ, Peterson NR, Bostwick DG, Lieber MM, Jacobsen SJ.

J Urol. 2000 May;163(5):1471-5.

PMID:
10751860
14.

Rising incidence of prostate cancer in Scotland: increased risk or increased detection?

Brewster DH, Fraser LA, Harris V, Black RJ.

BJU Int. 2000 Mar;85(4):463-72; discussion 472-3.

15.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

16.

Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.

Schwartz KL, Severson RK, Gurney JG, Montie JE.

Cancer. 1996 Sep 15;78(6):1260-6.

17.
18.

Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.

Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, Chute CG, Lieber MM.

JAMA. 1995 Nov 8;274(18):1445-9.

PMID:
7474190
20.

Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality.

Vutuc C, Waldhoer T, Madersbacher S, Micksche M, Haidinger G.

Eur J Cancer Prev. 2001 Oct;10(5):425-8.

PMID:
11711757
Items per page

Supplemental Content

Write to the Help Desk